7/15/2016 | PP | CytRx prices $18.3 million public stock offering at $0.70 per share
|
2/9/2016 | PP | CytRx secures $40 million through variable-rate loan due Feb. 1, 2020
|
2/8/2016 | PP | CytRx obtains up to $40 million in long-term financing from Hercules
|
7/24/2015 | PP | CytRx greenshoe exercised for $28.78 million public offering of stock
|
7/21/2015 | PP | CytRx prices $25.03 million public offering of common stock at $2.75
|
7/20/2015 | PP | CytRx reports that it plans to conduct public offering of common stock
|
2/5/2014 | PP | CytRx greenshoe exercised for $85.96 million public offering of stock
|
1/31/2014 | PP | CytRx firms pricing for $74.75 million public stock offering at $6.50
|
1/30/2014 | PP | CytRx announces it plans to price public offering of its common stock
|
10/11/2013 | PP | CytRx greenshoe lifts public offering of stock to $25.88 million
|
10/9/2013 | PP | CytRx prices $22.5 million public offering of common stock at $2.25
|
10/8/2013 | PP | CytRx reports that it will price a public offering of its common stock
|
12/6/2012 | CVHYPF | CytRx files $100 million shelf covering stock, warrants, preferreds
|
10/19/2012 | PP | CytRx: $3 million greenshoe exercised in $20 million public stock sale
|
10/18/2012 | PP | CytRx prices $20 million public stock sale with $3 million greenshoe
|
10/17/2012 | PP | CytRx announces plans to price public offering of common stock
|
7/27/2011 | PP | CytRx prices $20.38 million public offering of shares with warrants
|
7/26/2011 | PP | CytRx reports plans to price public offering of common stock, warrants
|
11/8/2010 | CVHYPF | CytRx files $100 million shelf registration for preferreds, stock
|
7/28/2009 | PP | New Issue: CytRx hopes to raise $19.98 million via registered offering of shares
|
7/24/2009 | PP | New Issue: CytRx plans $20.04 million registered direct offering of common stock
|
7/24/2009 | PP | Market Commentary: CytRx to sell equity; Prolor retires credit line with placement funds; Cyclacel plans offering
|
4/19/2007 | PP | Market Commentary: Castle Brands prepares to seal $20.89 million private placement; LCC wraps $17 million stock offering
|
4/18/2007 | PP | New Issue: CytRx secures $36.98 million from private placement of stock
|
4/18/2007 | PP | Market Commentary: CytRx to settle $36.98 million stock offering; Cel-Sci wraps $15 million private placement of shares
|
11/13/2006 | BT | CytRx: third-quarter net loss slightly down from prior-year period
|
11/9/2006 | BT | Market Commentary: Thermage, ActivBiotics IPOs on tap at lower ranges; Millennium, Elan market bonds; Vasogen off
|
10/31/2006 | BT | Market Commentary: Alnylam, CytRx gain with Sirna; Antigenics gains; Viragen sinks; ZymoGenetics off ahead of results
|
10/30/2006 | BT | Market Commentary: Sirna soars after hours on Merck $1.1 billion buyout; Emisphere plunges 24%; Point better by 19%
|
9/26/2006 | BT | CytRx: arimoclomol shown to be safe, well tolerated in phase 2a ALS study
|
8/29/2006 | BT | CytRx gets $24.5 million for 1% royalty interest in Lou Gehrig's therapy
|
7/31/2006 | BT | CytRx says phase 1 study shows HIV vaccine elicits immune response, is well-tolerated at lower doses
|
7/24/2006 | BT | CytRx completes patient dosing, follow-up in Lou Gehrig's disease trial
|
5/23/2006 | BT | CytRx 1Q net loss widens to $4.2 million, revenue increases
|
4/4/2006 | BT | CytRx completes enrollment in phase 2a clinical trial for Lou Gehrig's disease
|
3/31/2006 | BT | CytRx says net loss tightens to $15.1 million despite 57% drop in 2005 revenue
|
3/9/2006 | BT | CytRx applies RNAi technologies to drug discovery, diabetes treatment
|
3/6/2006 | BT | CytRx announces new support of RNAi screening for obesity, diabetes
|
3/3/2006 | PP | Market Commentary: North American Palladium plans $58.5 million note offering; CytRx prepares to close $13.42 million PIPE
|
3/3/2006 | BTPP | New Issue: CytRx prepares to close $13.42 million private placement of units
|
2/13/2006 | BT | CytRx begins extension trial of arimoclomol for Lou Gehrig's disease
|
2/2/2006 | BT | CytRx research finds suppression of RIP140 controls insulin
|
1/30/2006 | BT | CytRx to form subsidiary to accelerate RNAi therapeutics programs
|
1/23/2006 | BT | CytRx to extend phase 2 trial of arimoclomol for Lou Gehrig's disease
|
1/4/2006 | BT | CytRx regains compliance with Nasdaq listing requirements
|
12/15/2005 | BT | CytRx to develop diabetes/obesity drug based on University of Massachusetts fat cell drug targets
|
12/6/2005 | BT | CytRx given an extra 180 days to comply with Nasdaq listing requirements
|
1/21/2005 | PP | New Issue: CytRx to raise $21.3 million in private placement of shares
|
1/21/2005 | PP | Market Commentary: Private placement volume remains flat; Napster plans $52.18 million offering
|